FDA Approves AI-Powered Automated Plate Assessment System

The FDA granted approval to Clever Culture Systems, a venture between Australian medical firm LBT Innovations Limited and lab equipment maker Hettich AG of Switzerland, for the Automated Plate Assessment System (APAS). APAS aims to automate and expedite the process of analyzing microorganism cultures in order to guide and expedite patient treatment.

The US FDA de novo approval was granted following a successful one-year clinical trial where APAS matched, and often exceeded, the performance of trained microbiologists in screening and reading agar plates accurately and efficiently.

APAS works by capturing a digital image of an agar plate and then utilizing artificial intelligence algorithms to read and analyze any microorganism growth in less than 20 seconds. A trained microbiologist typically requires one minute to complete this process. Based on these findings, some studies suggest that APAS could cut processing costs up to 40 percent. Additionally, by shortening the turnaround time between receiving a specimen and reporting the results to providers, APAS allows for earlier diagnosis and treatment identification for patients, which improves patient quality of care and will potentially save lives.

LBT Innovations and other medical development companies, such as bioMérieux, continue to work on expanding the role of automation in microbiology laboratories. Given the estimate that 2.1 billion microorganism cultures are processed annually, the financial, operational, and clinical implications of automated systems become tremendous.

Kenan Raddawi, M.D., studied medicine at Damascus University Faculty of Medicine in Syria before the Syrian War required him to leave his country and transfer to Aureus University where he obtained his medical degree in 2016. He is greatly interested in staying up-to-date on innovative medical technologies and devices that are currently being developed worldwide and learning how these can improve patient care. He hopes to work on and develop medical technologies and devices of his own in the future through collaborating with other healthcare professionals.

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around

more

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around the world to participate in the upcoming “2nd World Congress on Advanced Cancer Science & Therapy” to be held at Dubai, UAE during January 28-29, 2019. The meeting for this year will revolve around the theme “An Assembly of Curious Facts and Cure for Cancer” thus relaying the most cutting-edge findings in this field.

The two-day meeting is going to be an event to look forward for its enlightening symposiums & workshops from established experts in cancer therapy, potential keynote talks from eminent speakers, informative oral sessions and innovative poster presentations.

Cancer Therapy 2019 is an extraordinary event that invites participants from different leading universities, clinical research institutions and various diagnostic companies to share their research experiences in all aspects of this rapidly expanding field and provides an opportunity to meet and communicate with leading doctors, surgeons, scientists, academic professionals from around the world and listen to top speakers on new developments that impact and advance future of cancer science. It serves as a global platform to know about the current developments and new approaches in the field of cancer science and therapy. It will also prove to be a brilliant open door for businesses keen on expanding their global market reach. This event is an effort to understand the underlying new techniques which are amended to increase effectiveness, accuracy, sustainability, and quality of life.